Bettina Wingelhofer
Bettina Wingelhofer
CRUK Manchester Institute
Verified email at manchester.ac.uk - Homepage
Title
Cited by
Cited by
Year
Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer
B Wingelhofer, HA Neubauer, P Valent, X Han, SN Constantinescu, ...
Leukemia 32 (8), 1713-1726, 2018
1012018
Pharmacologic inhibition of STAT5 in acute myeloid leukemia
B Wingelhofer, B Maurer, EC Heyes, AA Cumaraswamy, A Berger-Becvar, ...
Leukemia 32 (5), 1135-1146, 2018
772018
Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma
C Gauglhofer, J Paur, WC Schrottmaier, B Wingelhofer, D Huber, ...
Carcinogenesis 35 (10), 2331-2338, 2014
402014
O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies
P Freund, MA Kerenyi, M Hager, T Wagner, B Wingelhofer, HTT Pham, ...
Leukemia 31 (10), 2132-2142, 2017
332017
The ERBB-STAT3 axis drives Tasmanian devil facial tumor disease
L Kosack, B Wingelhofer, A Popa, A Orlova, B Agerer, B Vilagos, P Majek, ...
Cancer Cell 35 (1), 125-139. e9, 2019
272019
Malignant phenotypes in metastatic melanoma are governed by SR-BI and its association with glycosylation and STAT5 activation
K Kinslechner, D Schörghofer, B Schütz, M Vallianou, B Wingelhofer, ...
Molecular Cancer Research 16 (1), 135-146, 2018
172018
High activation of STAT5A drives peripheral T-cell lymphoma and leukemia
B Maurer, H Nivarthi, B Wingelhofer, HTT Pham, M Schlederer, T Suske, ...
Haematologica 105 (2), 435, 2020
152020
Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells
B Peter, S Bibi, G Eisenwort, B Wingelhofer, D Berger, G Stefanzl, K Blatt, ...
Leukemia 32 (4), 1016-1022, 2018
152018
The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma
A Keller, B Wingelhofer, B Peter, K Bauer, D Berger, S Gamperl, ...
Veterinary and comparative oncology 16 (1), 55-68, 2018
152018
Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia
G Deb, B Wingelhofer, FMR Amaral, A Maiques-Diaz, JA Chadwick, ...
Leukemia 34 (5), 1266-1277, 2020
132020
Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas
A Orlova, B Wingelhofer, HA Neubauer, B Maurer, A Berger-Becvar, ...
Expert opinion on therapeutic targets 22 (1), 45-57, 2018
122018
Preloading with L-BPA, L-tyrosine and L-DOPA enhances the uptake of [18F] FBPA in human and mouse tumour cell lines
B Wingelhofer, K Kreis, S Mairinger, V Muchitsch, J Stanek, T Wanek, ...
Applied Radiation and Isotopes 118, 67-72, 2016
122016
Emerging epigenetic therapeutic targets in acute myeloid leukemia
B Wingelhofer, TCP Somervaille
Frontiers in oncology 9, 850, 2019
92019
STAT5 is expressed in CD34+/CD38− stem cells and serves as a potential molecular target in ph-negative myeloproliferative neoplasms
E Hadzijusufovic, A Keller, D Berger, G Greiner, B Wingelhofer, ...
Cancers 12 (4), 1021, 2020
62020
STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway
A Swoboda, R Soukup, O Eckel, K Kinslechner, B Wingelhofer, ...
Oncogene 40 (6), 1091-1105, 2021
32021
The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma (vol 16, pg 55, 2018)
A Keller, B Wingelhofer, B Peter
VETERINARY AND COMPARATIVE ONCOLOGY 17 (3), 446-447, 2019
2019
Genome-Wide CRISPR-Cas9 Screen Identifies Sensitizers to LSD1 Inhibition in MLL-Translocated Human AML Cells
G Deb, B Wingelhofer, E Williams, HS Leong, TCP Somervaille
Blood 132, 178, 2018
2018
Cover Image, Volume 16, Issue 1
A Keller, B Wingelhofer, B Peter, K Bauer, D Berger, S Gamperl, ...
Veterinary and Comparative Oncology 16 (1), i-i, 2018
2018
STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pigmentation pathway
A Swoboda, R Soukup, K Kinslechner, B Wingelhofer, D Schörghofer, ...
bioRxiv, 422832, 2018
2018
Characterization of novel STAT5 inhibitors to interfere with the oncogenic activities of STAT5 in hematopoietic diseases
B Wingelhofer, B Maurer, EC Heyes, P Freund, AA Cumaraswamy, J Park, ...
Cancer Research 77 (13 Supplement), 1184-1184, 2017
2017
The system can't perform the operation now. Try again later.
Articles 1–20